See more : 10X Capital Venture Acquisition Corp. II (VCXAU) Income Statement Analysis – Financial Results
Complete financial analysis of Maison Solutions Inc. Class A Common Stock (MSS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Maison Solutions Inc. Class A Common Stock, a leading company in the Grocery Stores industry within the Consumer Defensive sector.
You may be interested
- Wakita & Co.,LTD. (8125.T) Income Statement Analysis – Financial Results
- Deterra Royalties Limited (DETRF) Income Statement Analysis – Financial Results
- Netcare Limited (NWKHY) Income Statement Analysis – Financial Results
- Agrify Corporation (AGFY) Income Statement Analysis – Financial Results
- Puriblood Medical Co., Ltd. (6847.TWO) Income Statement Analysis – Financial Results
Maison Solutions Inc. Class A Common Stock (MSS)
About Maison Solutions Inc. Class A Common Stock
Maison Solutions Inc., together with its subsidiaries, operates as the specialty grocery retailer in California. The company offers perishable products, such as meat, seafood, vegetables, and fruit; non-perishable products, including grocery products comprising cooking utensils, canned foods, Chinese and Asian seasonings and spices, and snacks, as well as liquor, cigarette, lottery, newspaper, reusable bag, non-food, and health products, and general merchandise, beauty care, pharmacy, fuel, and other items and services in its stores. It also offers its products online. The company was formerly known as Maison International, Inc. and changed its name to Maison Solutions Inc. in September 2021. Maison Solutions Inc. was incorporated in 2019 and is based in Monterey Park, California.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 58.04M | 55.40M | 41.98M | 41.20M |
| Cost of Revenue | 46.42M | 42.95M | 33.70M | 32.88M |
| Gross Profit | 11.62M | 12.45M | 8.29M | 8.31M |
| Gross Profit Ratio | 20.02% | 22.48% | 19.74% | 20.17% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 4.17M | 3.89M | 3.00M | 1.75M |
| Selling & Marketing | 10.16M | 8.48M | 6.11M | 6.01M |
| SG&A | 14.33M | 12.37M | 9.11M | 7.76M |
| Other Expenses | 0.00 | 1.85M | 155.82K | 968.65K |
| Operating Expenses | 14.33M | 12.37M | 9.11M | 7.76M |
| Cost & Expenses | 60.75M | 55.32M | 42.81M | 40.64M |
| Interest Income | 0.00 | 42.61K | 43.48K | 0.00 |
| Interest Expense | 124.26K | 0.00 | 0.00 | 59.21K |
| Depreciation & Amortization | 461.87K | 370.53K | 437.41K | 578.87K |
| EBITDA | -2.24M | 454.18K | -389.18K | 1.13M |
| EBITDA Ratio | -3.86% | 0.82% | -0.93% | 2.75% |
| Operating Income | -2.70M | 83.65K | -826.59K | 553.40K |
| Operating Income Ratio | -4.66% | 0.15% | -1.97% | 1.34% |
| Total Other Income/Expenses | -242.46K | 1.89M | 199.30K | 909.44K |
| Income Before Tax | -2.95M | 1.98M | -627.29K | 1.46M |
| Income Before Tax Ratio | -5.08% | 3.57% | -1.49% | 3.55% |
| Income Tax Expense | 440.56K | 336.49K | 27.74K | 436.06K |
| Net Income | -3.34M | 1.25M | -562.74K | 904.08K |
| Net Income Ratio | -5.75% | 2.26% | -1.34% | 2.19% |
| EPS | -0.19 | 0.07 | -0.03 | 0.05 |
| EPS Diluted | -0.19 | 0.07 | -0.03 | 0.05 |
| Weighted Avg Shares Out | 17.91M | 18.50M | 18.50M | 18.50M |
| Weighted Avg Shares Out (Dil) | 17.91M | 18.50M | 18.50M | 18.50M |
Maison Solutions Completes El Monte Store Renovation
MONTEREY PARK, CA / ACCESSWIRE / October 28, 2024 / Maison Solutions Inc. (NASDAQ:MSS) ("Maison Solutions" or the "Company"), a U.S.-based specialty grocery retailer offering traditional Asian and international food and merchandise, announced it has completed the renovation of its...
Maison Solutions Reports First Quarter 2025 Financial Results
MONTEREY PARK, CA / ACCESSWIRE / September 23, 2024 / Maison Solutions Inc. (NASDAQ:MSS) ("Maison Solutions" or the "Company"), a U.S.-based specialty grocery retailer offering traditional Asian and international food and merchandise, today announced financial results for the first quarter...
Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
- Confirmed partial responses (PRs) doubled to four since ASCO GI in MSS CRC patients without liver and peritoneal metastases for overall response rate (ORR) of 24% (4/17) with ADG126 10 mg/kg every three weeks (Q3W) in combination with pembrolizumab...
MAISON ALERT: Bragar Eagel & Squire, P.C. is Investigating Maison Solutions Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Maison Solutions Inc. (NASDAQ: MSS) on behalf of long-term stockholders following a class action complaint...
Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced results from an investigator-sponsored trial (IST) of botensilimab and balstilimab (BOT/BAL) in the neoadjuvant setting for colon cancer. Data were...
Syndax Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC
– IDMC recommendation to advance based on favorable safety profile observed in Phase 1a portion of trial – WALTHAM, Mass. , June 6, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer...
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced a novel analysis from the Phase 1b trial of botensilimab in combination with balstilimab (BOT/BAL) in relapsed/refractory microsatellite stable colorectal...
Maison Solutions Releases Post-Acquisition Webinar Detailing Recent Expansion into Arizona
MONTEREY PARK, CA / ACCESSWIRE / April 19, 2024 / Maison Solutions Inc. ("Maison Solutions" or the "Company"), (NASDAQ:MSS), a U.S.-based specialty grocery retailer offering traditional Asian and international food and merchandise, today released a pre-recorded webinar providing additional information...
Maison Solutions to Share Additional Details Regarding Expansion into Arizona on Friday, April 19, 2024 at 11:00 a.m. ET
Acquisition of Three-Store Lee Lee International Supermarket to More than Double Size of Maison MONTEREY PARK, CA / ACCESSWIRE / April 15, 2024 / Maison Solutions Inc. ("Maison Solutions" or the "Company"), (NASDAQ:MSS), a U.S.-based specialty grocery retailer offering traditional...
Maison Solutions Expands into Arizona with Acquisition of Three-Store Lee Lee International Supermarkets Chain
-- Transaction More than Doubles Size of Maison; Expands Geographic Footprint to New Region -- MONTEREY PARK, CA / ACCESSWIRE / April 10, 2024 / Maison Solutions Inc. ("Maison Solutions" or the "Company"), (NASDAQ:MSS), a U.S.-based specialty grocery retailer offering...
Source: https://incomestatements.info
Category: Stock Reports